GeneFab LLC, a contract research, development, and manufacturing organization (CRDMO), reported a transaction with Senti Biosciences, Inc., in which GeneFab would sublease Senti Bio’s cGMP facility, a portion of which is subject to certain conditions. GeneFab would also acquire Senti Bio’s chemistry, manufacturing, and controls (CMC) capabilities for approximately $38 million. As part of the transaction, departing Senti Bio co-founder and chief technology officer, Philip Lee, will become CEO of ...